<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03201068</url>
  </required_header>
  <id_info>
    <org_study_id>41697</org_study_id>
    <nct_id>NCT03201068</nct_id>
  </id_info>
  <brief_title>Probiotic Supplement and Microbiome, Immune System and Metabolic Syndrome</brief_title>
  <official_title>Impact of a Probiotic Supplement on the Microbiome, Immune System, and Metabolic Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Clorox Company</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will define the impact of a probiotic supplement on microbiome, immune system, and&#xD;
      metabolic syndrome. This study will determine the degree to which a probiotic supplement can&#xD;
      1) improve metabolic markers and metrics of metabolic syndrome, 2) alter microbiota&#xD;
      composition and function, 3) impact microbiota metabolites, short-chain fatty acids-potential&#xD;
      normalizers of metabolic and immune dysfunction, and 4) regulate immune status and function&#xD;
      including reducing chronic, systemic inflammation as assessed by high dimensional immune&#xD;
      profiling.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The centrality of the gut microbiota to human health has emerged in just the last decade,&#xD;
      with the last three years implicating our modern, deteriorated gut microbiota in numerous&#xD;
      chronic diseases. It is likely dietary changes in the last half-century consistent with&#xD;
      adoption of the Western diet have had an adverse impact on the gut microbiota. A critically&#xD;
      important next step in this field of research is to identify how different probiotic&#xD;
      supplements can potentially restore the microbiota in alignment with the optimization of&#xD;
      human health, particularly in regard to the reversal or prevention of chronic diseases&#xD;
      including obesity, metabolic syndrome, and inflammatory bowel disease. This study is designed&#xD;
      to elicit and contrast the amount of increase in microbiota diversity and related metabolic&#xD;
      output achievable following consumption of a probiotic supplement commonly available to the&#xD;
      general population. The results could contribute to dietary recommendations for reversing the&#xD;
      chronic disease epidemics of westernization.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 14, 2017</start_date>
  <completion_date type="Actual">December 4, 2018</completion_date>
  <primary_completion_date type="Actual">November 16, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Metabolic syndrome parameters: Waist Circumference, Blood pressure, Triglycerides, HDL-cholesterol, and Fasting Glucose.</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from Baseline (week 4) in the number of subjects presenting 3 of the 5 parameters for metabolic syndrome (waist circumference, blood pressure, triglycerides, HDL-cholesterol, and fasting glucose) at 14 weeks (end of intervention).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Microbiota composition</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from baseline (week 4) in 16S rRNA enumeration at 14 weeks (end of intervention), determined using Illumina-based sequencing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Microbiota metabolites</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from Baseline (week 4) in short-chain fatty acids (SCFA) at 14 weeks (end of intervention).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytokines</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from Baseline (week 4) in cytokines at 14 weeks (end of intervention).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Chemokines</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from Baseline (week 4) in chemokines at 14 weeks (end of intervention).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hs-C Reactive Protein (CRP)</measure>
    <time_frame>Baseline (week 4) and end of intervention (week 14)</time_frame>
    <description>10-week change from Baseline (week 4) in hs-CRP at 14 weeks (end of intervention).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Metabolic Syndrome</condition>
  <condition>Microbiome</condition>
  <condition>Immune Function</condition>
  <condition>Inflammation</condition>
  <arm_group>
    <arm_group_label>Probiotic supplement</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Renew Life Formulas, Inc</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Probiotic supplement</intervention_name>
    <description>Probiotic supplement capsule</description>
    <arm_group_label>Probiotic supplement</arm_group_label>
    <other_name>Renew Life Formulas, Inc</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo capsule</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 and older&#xD;
&#xD;
          -  Must have metabolic syndrome as defined by having at least 2 of the 5 criteria per&#xD;
             either ATP III guidelines OR International Diabetes Federation (IDF) guidelines:&#xD;
&#xD;
        ATP III guidelines:&#xD;
&#xD;
          1. Abdominal obesity, defined as a waist circumference in men ≥102 cm (40 in) and in&#xD;
             women ≥88 cm (35 in)&#xD;
&#xD;
          2. Serum triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment for elevated&#xD;
             triglycerides&#xD;
&#xD;
          3. Serum high-density lipoprotein (HDL) cholesterol &lt;40 mg/dL (1 mmol/L) in men and &lt;50&#xD;
             mg/dL (1.3 mmol/L) in women or drug treatment for low HDL cholesterol&#xD;
&#xD;
          4. Blood pressure ≥130/85 mmHg or drug treatment for elevated blood pressure&#xD;
&#xD;
          5. Fasting plasma glucose (FPG) ≥100 mg/dL (5.6 mmol/L) or drug treatment for elevated&#xD;
             blood glucose&#xD;
&#xD;
        International Diabetes Federation Guidelines:&#xD;
&#xD;
          1. Increased waist circumference, with ethnic-specific waist circumference cut-points:&#xD;
&#xD;
             White and all other ethnic groups - Men ≥ 94 cm; Women ≥ 80 cm South Asians, Chinese,&#xD;
             and Japanese - Men ≥ 90 cm; Women ≥ 80 cm&#xD;
&#xD;
             PLUS any two of the following:&#xD;
&#xD;
          2. Triglycerides ≥150 mg/dL (1.7 mmol/L) or treatment for elevated triglycerides&#xD;
&#xD;
          3. HDL cholesterol &lt;40 mg/dL (1.03 mmol/L) in men or &lt;50 mg/dL (1.29 mmol/L) in women, or&#xD;
             treatment for low HDL&#xD;
&#xD;
          4. Systolic blood pressure ≥130, diastolic blood pressure ≥85, or treatment for&#xD;
             hypertension&#xD;
&#xD;
          5. FPG ≥100 mg/dL (5.6 mmol/L) or previously diagnosed type 2 diabetes; an oral glucose&#xD;
             tolerance test is recommended for patients with an elevated fasting plasma glucose,&#xD;
             but not required.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥ 40&#xD;
&#xD;
          -  LDL &gt;160 mg/dL.&#xD;
&#xD;
          -  Vital signs outside of acceptable range at Screening Visit: blood pressure &gt;159/99,&#xD;
             oral temperature ≥ 100°F, pulse &gt;100.&#xD;
&#xD;
          -  Use of any of the following drugs within the last 6 months:systemic antibiotics (must&#xD;
             be discontinued and avoided for 2 months prior to the study start), antifungals,&#xD;
             antivirals or antiparasitics (intravenous, intramuscular, or oral); oral, intravenous,&#xD;
             intramuscular, nasal or inhaled corticosteroids; cytokines; methotrexate or&#xD;
             immunosuppressive cytotoxic agents;&#xD;
&#xD;
          -  Use of large doses of commercial probiotics consumed within the last 6 months (greater&#xD;
             than or equal to 108 cfu or organisms per day) - includes tablets, capsules, lozenges,&#xD;
             chewing gum or powders in which probiotic is a primary component (must be discontinued&#xD;
             and avoided for one month prior to the study start). Ordinary dietary components such&#xD;
             as fermented beverages/milks, yogurts, foods do not apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christopher D Gardner, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 23, 2017</study_first_submitted>
  <study_first_submitted_qc>June 26, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2017</study_first_posted>
  <last_update_submitted>September 26, 2019</last_update_submitted>
  <last_update_submitted_qc>September 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Justin L. Sonnenburg</investigator_full_name>
    <investigator_title>Associate Professor of Microbiology and Immunology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Inflammation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

